Business
Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and
About this update from Entrada Therapeutics, Inc.
[{"type":"text","content":"BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 12:10 p.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com, or by clicking here. A replay will be available on the Entrada website for 90 days following the event. About Entrada Therapeutics Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). Entrada/Investor ContactKarla MacDonaldVP, Corporate [email protected] Media ContactAulani CapuchinReal [email protected] (559) 355-2673 \nSource: Entrada Therapeutics, Inc.","length":4070,"tagName":"div"}]